EP1230360A4 - 15 human secreted proteins - Google Patents

15 human secreted proteins

Info

Publication number
EP1230360A4
EP1230360A4 EP00976752A EP00976752A EP1230360A4 EP 1230360 A4 EP1230360 A4 EP 1230360A4 EP 00976752 A EP00976752 A EP 00976752A EP 00976752 A EP00976752 A EP 00976752A EP 1230360 A4 EP1230360 A4 EP 1230360A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976752A
Other languages
German (de)
French (fr)
Other versions
EP1230360A2 (en
Inventor
Henrik S Olsen
George Komatsoulis
D Roxanne Duan
Reinhard Ebner
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1230360A2 publication Critical patent/EP1230360A2/en
Publication of EP1230360A4 publication Critical patent/EP1230360A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP00976752A 1999-11-09 2000-11-01 15 human secreted proteins Withdrawn EP1230360A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16434499P 1999-11-09 1999-11-09
US164344P 1999-11-09
US19529600P 2000-04-07 2000-04-07
US195296P 2000-04-07
US22136700P 2000-07-27 2000-07-27
US221367P 2000-07-27
PCT/US2000/030039 WO2001034768A2 (en) 1999-11-09 2000-11-01 15 human secreted proteins

Publications (2)

Publication Number Publication Date
EP1230360A2 EP1230360A2 (en) 2002-08-14
EP1230360A4 true EP1230360A4 (en) 2003-04-02

Family

ID=27389003

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976752A Withdrawn EP1230360A4 (en) 1999-11-09 2000-11-01 15 human secreted proteins

Country Status (5)

Country Link
EP (1) EP1230360A4 (en)
JP (1) JP2003513662A (en)
AU (1) AU1448701A (en)
CA (1) CA2389722A1 (en)
WO (1) WO2001034768A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
JP2003521928A (en) * 2000-01-25 2003-07-22 ハイセック，インコーポレーテッド Methods and materials for preadipocyte factor-1-like (Pref-1-like) polypeptides and polynucleotides
ATE385504T1 (en) 2000-06-06 2008-02-15 Bristol Myers Squibb Co NUCLEIC ACIDS AND POLYPEPTIDES RELATED TO B7 AND THEIR USES FOR IMMUNE MODULATION
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2002351505B2 (en) * 2001-10-19 2008-04-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU2003245536A1 (en) * 2002-06-10 2003-12-22 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
HUE039237T2 (en) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-h1 and pd-1 in treatment of renal cell carcinoma
JPWO2006101272A1 (en) * 2005-03-25 2008-09-04 株式会社リバース・プロテオミクス研究所 Drug discovery target protein and target gene, and screening method
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
CN101636179B (en) 2006-11-07 2012-10-10 默沙东公司 Antagonists of pcsk9
WO2008118386A2 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
EP2493505A4 (en) 2009-10-30 2013-06-12 Merck Sharp & Dohme Ax1 and ax189 pcsk9 antagonists and variants
JP2013509194A (en) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション AX213 and AX132PCSK9 antagonists and variants
CA2850245C (en) * 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
EP2847223B1 (en) 2012-05-07 2019-03-27 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
JP7267014B2 (en) 2016-06-21 2023-05-01 アイオー バイオテック エーピーエス PDL1 peptides for use in cancer vaccines
CN110352242A (en) 2016-12-23 2019-10-18 哈佛大学的校长及成员们 The gene editing of PCSK9

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042470A1 (en) * 1998-02-18 1999-08-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2001021631A2 (en) * 1999-09-20 2001-03-29 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505405A (en) * 1996-07-24 2001-04-24 ユニバーシティ・オブ・メリーランド Butyrophilin gene promoter and its use
JPH1175859A (en) * 1997-09-08 1999-03-23 R P R Jienseru Kk Apoptosis-related gene expressible virus vector system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042470A1 (en) * 1998-02-18 1999-08-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2001021631A2 (en) * 1999-09-20 2001-03-29 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLEMAN T A ET AL: "Production and purification of novel secreted human proteins", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 190, no. 1, 29 April 1997 (1997-04-29), pages 163 - 171, XP004064398, ISSN: 0378-1119 *
See also references of WO0134768A3 *

Also Published As

Publication number Publication date
JP2003513662A (en) 2003-04-15
AU1448701A (en) 2001-06-06
WO2001034768A2 (en) 2001-05-17
EP1230360A2 (en) 2002-08-14
CA2389722A1 (en) 2001-05-17
WO2001034768A3 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
EP1218408A4 (en) 32 human secreted proteins
EP1212343A4 (en) 52 human secreted proteins
EP1181390A4 (en) 27 human secreted proteins
EP1224285A4 (en) 27 human secreted proteins
EP1212342A4 (en) 18 human secreted proteins
EP1226231A4 (en) 19 human secreted proteins
EP1175438A4 (en) 62 human secreted proteins
EP1192278A4 (en) 48 human secreted proteins
EP1192176A4 (en) 49 human secreted proteins
EP1165827A4 (en) 45 human secreted proteins
EP1175439A4 (en) 49 human secreted proteins
EP1159284A4 (en) 33 human secreted proteins
EP1189917A4 (en) 48 human secreted proteins
EP1185543A4 (en) 50 human secreted proteins
EP1224201A4 (en) 32 human secreted proteins
EP1173477A4 (en) 49 human secreted proteins
EP1203005A4 (en) 25 human secreted proteins
EP1206573A4 (en) 26 human secreted proteins
EP1169332A4 (en) 49 human secreted proteins
EP1171460A4 (en) 48 human secreted proteins
EP1144614A4 (en) 33 human secreted proteins
EP1165602A4 (en) 49 human secreted proteins
EP1165828A4 (en) 50 human secreted proteins
EP1228082A4 (en) 29 human secreted proteins
EP1185285A4 (en) 49 human secreted proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020603

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HUMAN GENOME SCIENCES, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20030218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20051005